Breast Cancer
Conference Coverage
NLR correlates with survival in advanced breast cancer
Key clinical point: Neutrophil lymphocyte ratio (NLR) can be correlated with poor disease-specific survival in stage IV breast cancer and the...
News
Histologic information can’t replace recurrence score
Key clinical point: A combination of three histologic variables (tumor size, grade, and cellular proliferation marker Ki67) failed to accurately...
Original Report
A qualitative exploration of supports and unmet needs of diverse young women with breast cancer
Conference Coverage
DCIS recurrences have declined significantly
Key clinical point: Recurrence rates of DCIS in patients treated with breast-conserving surgery declined significantly from 1978 through 2010....
Conference Coverage
Radiation + lumpectomy tied to increased survival in older women with TNBC
Key clinical point: Radiation added to breast-conserving surgery in women 70 and older with early-stage triple-negative breast cancer was...
News
LCIS: 2% annual cancer risk, less than 1% with chemoprevention
Key clinical point: Women with lobular carcinoma in situ showed a 2% annual risk of developing breast cancer and a cumulative risk of 26% at 15...
News
More genomic instability found in breast tumors of black women
Key clinical point: Several differences in breast tumor genetics may explain the greater aggressiveness of breast cancer in black vs.
News
Fulvestrant may best anastrozole as first-line therapy
Fulvestrant may extend survival longer than does anastrozole when used as first-line therapy for locally advanced or metastatic estrogen receptor–...
News
DCIS: Recurrence risk rises after forgoing radiotherapy
Key clinical point: The risk of recurrence continues to rise for at least 12 years in patients with DCIS who had lumpectomy without radiotherapy....
News
For metastatic breast cancer, adding pertuzumab not cost-effective
Key clinical point: Adding pertuzumab to docetaxel plus trastuzumab combination therapy is not cost-effective for patients with metastatic HER2-...